The concept of PREP -taking an anti-infective therapy prior to exposure to a pathogen -is not in itself novel. This concept has been widely used in prophylaxis against opportunistic infections in the context of HIV infection, as well as more widely in infectious diseases such as malaria, influenza and rheumatic fever.
The putative effectiveness of PREP for HIV has been studied in animal models of sexual transmission of HIV. These studies have aimed to demonstrate proof-of-concept that the use of antiretroviral therapy can reduce the likelihood or rate at which HIV infection (or equivalent) occurs after exposure. The only published data thus far [1] , using tenofovir alone, showed that infection was delayed but not prevented. Preliminary results of these animal model studies (Heneine, presented at the 1st International Workshop on HIV Transmission; 11-12 August 2006; Toronto, Ontario, Canada) suggest that efficacy may be greater with emtricitabine (FTC), the combination of tenofovir disoproxil (TDF) and FTC, and intravenous TDF and FTC. Whilst animal model studies are limited by nature and have thus far predominantly used a rectal exposure methodology (which may not reflect the reality of exposure in the context of heterosexual HIV exposure in humans), they clearly justify the need for larger human studies.
In response to this perceived need and somewhat encouraging animal studies, multiple large-scale human studies have been planned and commenced across the globe. The primary outcomes of these studies are either safety or efficacy, and they have targeted different highrisk groups: men who have sex with men, intravenous drug users, commercial sex workers, and high-risk heterosexual women. Of the nine studies initially planned, four have already been discontinued either prior to or shortly after commencement. The reasons for discontinuation have been varied and include the inability to provide antiretroviral therapy should HIV infection occur, concerns about reduction in risk-behaviour counseling, the inability to afford PREP should it be shown to be effective, and concerns about the medical and laboratory conduct of trials. Five studies have, however, either commenced or are about to commence, in Africa, South America, USA and Thailand, and results will be reported between 2006 and 2009.
Multiple concerns about PREP remain, including the risk of toxicity secondary to PREP therapy, infection with resistant virus, cost-effectiveness, and the potential impact on risk behaviour (predominantly sexual activity) and 'condom displacement', i.e. a lessened perception of the need for (proven) barrier methods of HIV prevention that might result at a population level in increased rates of HIV transmission.
On the background of these justifiable concerns, the preliminary results of the first randomized study of PREP are encouraging (Peterson et al., presented at the XVI International AIDS Conference; 13-18 August 2006; Toronto). This study (TDF versus placebo), of high-risk women in Ghana, Cameroon, and Nigeria, was powered only to look at toxicity and suggested no increased risk of drug-associated toxicity with TDF compared with placebo. Whilst there were less seroconversions in the treatment arm, this did not achieve statistical significance -nor was it powered to investigate this. Those who are 'pro' PREP may argue that the number of seroconversions was greater in the placebo arm; those who are 'anti' PREP may argue that seroconversions did occur despite prophylaxis. Evidently, there is a need to await the formal results and those of the larger ongoing studies that are powered to consider efficacy. Arguably the most provocative finding of this study was that risk behaviour 'improved' during the conduct of the study: the number of new sexual partners and number of partners were reduced, and the use of condoms increased. Of the seroconversions in TDF recipients, thus far no resistance was detectable, consistent with the animal studies that have suggested no TDF-associated mutations when infection has occurred despite prophylaxis.
Whilst the above study suggested no deleterious effect of PREP on sexual risk-taking behaviour, it is notable that the initial study of male circumcision as a method of HIV prevention [2] showed that there was some suggestion of increased risk taking (number of sexual partners). In the current era of understanding, there remains an equipoise as to whether these interventions affect transmission or not. If a beneficial effect is subsequently noted, this equipoise will be lost and it will therefore be difficult to extrapolate from such randomized studies to future risk taking after implementation: i.e. although the current data suggest no increased risk taking in the context of a PREP study, if PREP is shown to be effective and it were introduced in clinical practice, the impact on behaviour might be different. Whilst such an impact on behaviour has not so far generally been seen with postexposure prophylaxis [3] , this remains of significant concern and requires prospective study should implementation occur.
Early cost-effectiveness modeling studies (Hill et al., presented at the 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006; Denver, Colorado, USA) have suggested that PREP may be cost-effective if used in high-risk populations, but sensitivity analyses will need to consider whether this is affected by any behaviour alteration as a result of efficacy and availability.
Further issues that will affect the efficacy of PREP in the 'real world' include awareness and applicability. Experts recognize that awareness of PEPSE (postexposure prophylaxis following sexual exposure) may be low even amongst high-risk groups, and the same is likely to be greater with PREP. Furthermore, even if awareness is raised, this does not ensure subsequent uptake. With PEPSE, for example, even if individuals are aware of its potential role after exposure, uptake is limited (Weatherburn et al., presented at the XVI International AIDS Conference; 13-18 August 2006; Toronto). It is notable that in the first randomized controlled trial of PREP (Peterson et al., presented at the XVI International AIDS Conference; 13-18 August 2006; Toronto), over half of those screened did not subsequently participate due to a variety of reasons including subsequent nonattendance, previously undiagnosed HIV infection, and coexisting conditions (including pregnancy) that precluded PREP use.
The potential use of PREP therefore needs to be considered within the overall context of HIV transmission and other prevention strategies. If PREP is shown to be effective it will need to be placed as part of a 'menu' that includes other clearly proven methods of preventioncondom use, abstinence, or reduced risk activity -and alongside other newer methods -such as circumcision, microbicides, vaccines, and highly active antiretroviral therapy (for which there is clear biologic plausibility and increasing cohort study evidence [4] (Kayitenkore et al., presented at the XVI International AIDS Conference; 13-18 August 2006; Toronto) to suggest that antiretroviral therapy per se may be effective in reducing HIV transmission).
It is highly unlikely that any individual method will be the panacea of HIV prevention. Should PREP be demonstrated as effective in any of the ongoing studies, careful monitoring of postintroduction effects (including risk behaviour and cost-effectiveness) will be essential. PREP must not be seen in isolation as a method of prevention without considering the overall effects on public as well as individual health.
